Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This study evaluated the lesional asphericity (ASP) in pretherapeutic somatostatin receptor (SSR) imaging...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2020-09-01
|
| Collection: | Diagnostics |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2075-4418/10/9/732 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|